Medical Communications

Showing 15 posts of 6408 posts found.

gsk_china_2_2_0_1

Cancer Research UK receives ‘success payment’ from GlaxoSmithKline

October 7, 2016 Medical Communications GSK, GlaxoSmithKline, University of Manchester, cancer research

CRT and the University of Manchester were rewarded financially for their collaboration developing molecules targeting cancer epigenetics. The agreement between …
top_ten_stories

Top Ten articles in the Pharma Industry this week

October 7, 2016 Medical Communications

The beginning of October has seen the failure of big drugs in clinical trials have a big knock-on effect for …
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016 Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal

October 6, 2016 Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion

The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016 Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
david_goldstein

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to …
oncology_no_border

Pharmafocus: Advances in Oncology available now!

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, oncology, pharmafocus supplement

The latest issue of Pharmafocus is now available, and with it comes Advances in Oncology, our supplement featuring all the …
top_ten_stories

Top Ten articles in the Pharma Industry this week

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Coming towards the end of September, we’ve had some major developments in drug trials and bad news for some of …
cancer_drugs_-_credit_derek_k

€10.2 billion lost every year across the EU due to fake medicines

September 30, 2016 Manufacturing and Production, Medical Communications EU, European Union Intellectual Property Office, France, Germany, Italy, Spain, united kingdom

A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …
The Gateway to Local Adoption Series

Latest content